This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (62)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Dermatologic Disorders  • Herpes  • Alert me on articles by topic  Social Bookmarking   What's this?

Stephen K. Tyring, MD, PhD; John M. Douglas, Jr, MD; Lawrence Corey, MD; Spotswood L. Spruance, MD; Jørgen Esmann, MD; for the Valaciclovir International Study Group

Arch Dermatol. 1998;134:185-191.

Objective  To compare valacyclovir hydrochloride with acyclovir in the treatment of recurrent genital herpes infection.

Design  A multicenter, double-blind, placebo-controlled, randomized, parallel-design study.

Setting  University clinics (dermatology, gynecology, and infectious diseases) and private practices.

Patients  One thousand two hundred patients with recurrent genital herpes simplex infections.

Interventions  Patients self-initiated oral therapy with 1000 mg of valacyclovir hydrochloride twice daily, 200 mg of acyclovir 5 times daily, or placebo for 5 days.

Main Outcome Measures  Resolution of all signs and symptoms of recurrent genital herpes infection.

Results  Both drugs were significantly more effective than placebo in speeding resolution of herpetic episodes (median duration, 4.8, 4.8, and 5.9 days, respectively); the hazards ratios for valacyclovir and acyclovir vs placebo were 1.66 (95% confidence interval [CI], 1.38-2.01) and 1.71 (95% CI, 1.41-2.06) (both P <.001). Similarly, valacyclovir and acyclovir significantly hastened lesion healing (hazards ratios vs placebo were 1.88 [95% CI, 1.53-2.32] and 1.90 [95% CI, 1.55-2.34], respectively; P <.001). Pain duration was shorter in valacyclovir- and acyclovir-treated patients (median, 2 vs 3 days). Viral shedding stopped 2.55 times faster in patients treated with valacyclovir and 2.24 times faster in patients treated with acyclovir than in patients treated with placebo. Aborted episodes, in which lesions did not progress beyond the macule or papule stage, tended to occur in more patients treated with valacyclovir (25.9%) or acyclovir (24.8%) than in patients treated with placebo (19.8%). Valacyclovir and acyclovir did not differ significantly with regard to their respective effects on any of the above efficacy parameters. The nature, severity, and frequency of adverse events did not differ among the 3 treatment groups.

Conclusions  Twice-daily valacyclovir was as effective and well tolerated in the treatment of recurrent genital herpes simplex virus infection as 5-times-daily acyclovir. Therefore, valacyclovir could prove a useful alternative to acyclovir when convenience of dosing or compliance issues are the prime considerations in treatment.

From the Department of Dermatology, University of Texas Medical Branch, Galveston (Dr Tyring); Denver Department of Public Health, Denver, Colo (Dr Douglas); Department of Laboratory Medicine, Virology Division, University of Washington, Seattle (Dr Corey); Department of Internal Medicine, University of Utah, Salt Lake City (Dr Spruance); and Department of Dermatology, Marselisborg Hospital, Aarhus, Denmark (Dr Esmann).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT | FULL TEXT  

The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures
MILLER et al.
Journal of the American Dental Association 2004;135:1311-1318.
ABSTRACT | FULL TEXT  

Hazard Ratio in Clinical Trials
Spruance et al.
Antimicrob. Agents Chemother. 2004;48:2787-2792.
FULL TEXT  

Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT | FULL TEXT  

Genital Herpes
Kimberlin and Rouse
NEJM 2004;350:1970-1977.
FULL TEXT  

Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir
Strand et al.
Sex. Transm. Infect. 2002;78:435-439.
ABSTRACT | FULL TEXT  

A Review of Antiviral Therapy for Herpes Labialis
Vander Straten et al.
Arch Dermatol 2001;137:1232-1235.
FULL TEXT  

A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes
Saiag et al.
J Antimicrob Chemother 1999;44:525-531.
ABSTRACT | FULL TEXT